摘要
目的:探讨乳腺癌组织ER、PR、p53及c-erbB-2癌基因蛋白表达与患者年龄、肿瘤体积、淋巴结转移及组织学类型的相关性。方法:采用免疫组化SP法检测126例乳腺癌患者乳腺组织中ER、PR、p53及c-erbB-2的表达,并分析其与临床意义的关系。结果:126例乳腺癌中,ER、PR、p53及c-erbB-2的阳性表达率分别为44.4%(56/126)、47.6%(60/126)、64.3%(81/126)、68.3%(86/126)。ER、PR的阳性表达率与患者年龄、肿瘤体积、有无淋巴结转移、肿瘤分期及组织学类型的差异无统计学意义(P>0.05);p53及c-erbB-2阳性表达率与有无淋巴结转移、年龄的差异有统计学意义(P<0.05),与肿瘤体积及组织学类型的差异无统计学意义(P>0.05)。结论:在乳腺癌患者中ER、PR、p53及c-erbB-2的联合检测可以用来指导临床用药和判断预后。
Objective： The expression of ER, PR, p53 and c - erbB - 2 was detected and the correlateion to age, tumor size, lymph node metastases and the structural type of breast cancers were studied. Methods： The expression of ER,PR,p53 and eerbB-2 in 126 cases of breast cancer tissue were assessed by SP method of immunohistochemistry. Results： Positive expression rates of ER, PR, p53 and c -erbB -2 in 126 cases of breast cancer tissue were 44.4 % （56/126） ,47.6 % （60/126） ,64.3% （81/126） ,68.3% （86/126）, the expression of ER,PR didnl correlate to age, tumor size, lymph node status, clinical stage and the structural type of breast cancers （ P 〉 0.05 ） . Expression of p53 and c - erbB -2 correlated with lymph node status, age （P 〈 0.05 ） , didnt correlate to tumor size and the structural type of breast cancer （ P 〉 0.05 ）. Conclusion： Combined detection of ER, PR, p53 and c - erbB - 2 oncogene in breast cancer can be used to guide clinical treatment and prognosis.
出处
《现代肿瘤医学》
CAS
2013年第2期314-316,共3页
Journal of Modern Oncology
